In recent research articles, new drugs such as GLP-1 (glucagon-like peptide-1 receptor agonists), SGLT2 (sodium-glucose cotransporter-2 inhibitors) and RAAS (renin-angiotensin-aldosterone system inhibitors) have been found to slow down the progression of DKD (110, 111). This evidence concerns the gene GCG and diabetic kidney disease.